NICE throws a wrench in Takeda's Ninlaro growth plans with second rejection

6th September 2017 Uncategorised 0

Last year, Takeda CEO Christophe Weber told investors that multiple myeloma med Ninlaro would surpass blockbuster Velcade as the company’s biggest-ever cancer product. But for now, it looks like it’ll have to do it without the help of England’s NHS.

More: NICE throws a wrench in Takeda's Ninlaro growth plans with second rejection
Source: fierce